{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:52Z","timestamp":1789506712098,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.drudis.2026.104714","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:40:16Z","timestamp":1780936816000},"page":"104714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Insight into human allogeneic CAR-T therapy: an open-access dataset"],"prefix":"10.1016","volume":"31","author":[{"given":"Natalia","family":"Obajtek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartek","family":"Lisowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seweryn","family":"Ulaszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Jesionek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Piejko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8614-0642","authenticated-orcid":false,"given":"Sebastian","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104714_b0005","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104714_b0010","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104714_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100677","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.drudis.2026.104714_b0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41375-021-01351-w","article-title":"Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"36","author":"Zhao","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2026.104714_b0025","unstructured":"FDA. Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous. Published November 28, 2023. Accessed December 22, 2025."},{"key":"10.1016\/j.drudis.2026.104714_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105597","article-title":"Computational modelling of CAR T-cell therapy: from cellular kinetics to patient-level predictions","volume":"113","author":"Murias-Closas","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.drudis.2026.104714_b0035","article-title":"Mathematical models and computational approaches in CAR-T therapeutics","volume":"16","author":"Putignano","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104714_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780145","article-title":"Strategies to circumvent the side-effects of immunotherapy using allogeneic CAR-T cells and boost its efficacy: results of recent clinical trials","volume":"12","author":"Smirnov","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104714_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103807","article-title":"Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R\/R ALL and NHL: a systematic review and meta-analysis","volume":"179","author":"Chen","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.drudis.2026.104714_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1585556","article-title":"Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis","volume":"16","author":"Biederst\u00e4dt","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104714_b0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00262-023-03586-1","article-title":"Allogeneic CAR-T cells with of HLA-A\/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies","volume":"73","author":"Chen","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.drudis.2026.104714_b0060","first-page":"146","article-title":"Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed\/refractory BCP-ALL","volume":"142","author":"Del Bufalo","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104714_b0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2026.104714_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102516","article-title":"CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study","volume":"70","author":"Xiao","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.drudis.2026.104714_b0075","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","article-title":"Sleeping Beauty\u2013engineered CAR T cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104714_b0080","article-title":"Acute graft-versus-host disease after humanized anti-CD19-CAR T therapy in relapsed B-ALL patients after allogeneic hematopoietic stem cell transplant","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104714_b0085","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.21037\/tcr-22-174","article-title":"Allogeneic CAR-T bridging to allo-HSCT as a treatment strategy for refractory adult Burkitt\u2019s lymphoma: a case report","volume":"11","author":"Cheng","year":"2022","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.drudis.2026.104714_b0090","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104714_b0095","article-title":"Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104714_b0100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","article-title":"Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial","volume":"31","author":"Pan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104714_b0105","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.drudis.2026.104714_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1254010","article-title":"Demethylating agents in combination with CD7-targeted CAR-T for the successful treatment of a case with mixed-phenotype acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report","volume":"14","author":"Han","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104714_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1389227","article-title":"Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed\/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission","volume":"15","author":"Miao","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104714_b0120","article-title":"Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vector","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104714_b0125","article-title":"Sequential autologous CAR-T and allogeneic CAR-T therapy successfully treats central nervous system involvement relapsed\/refractory ALL: a case report and literature review","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104714_b0130","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase i trials using sleeping beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104714_b0135","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO-24-01933","article-title":"Allogeneic chimeric antigen receptor T-cell products Cemacabtagene Ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: Phase I experience from the ALPHA2\/ALPHA clinical studies","volume":"43","author":"Locke","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104714_b0140","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104714_b0145","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1027469","article-title":"Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia","volume":"4","author":"Dai","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drudis.2026.104714_b0150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CJI.0000000000000257","article-title":"Chimeric antigen receptor-modified donor lymphocyte infusion improves the survival of acute lymphoblastic leukemia patients with relapsed diseases after allogeneic hematopoietic stem cell transplantation","volume":"42","author":"Wang","year":"2019","journal-title":"J Immunother"},{"key":"10.1016\/j.drudis.2026.104714_b0155","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70081","article-title":"Clinical outcomes of CD7 CAR-T cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma patients","volume":"43","author":"Xiao","year":"2025","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104714_b0160","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104714_b0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.drudis.2026.104714_b0170","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41409-020-01140-6","article-title":"Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Hua","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.drudis.2026.104714_b0175","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104714_b0180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104714_b0185","article-title":"CAR-Tography of modeling approaches and opportunities in cellular therapy of cancer","volume":"66","author":"Jesionek","year":"2026","journal-title":"Folia Med Cracov"},{"key":"10.1016\/j.drudis.2026.104714_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcdb.2025.103646","article-title":"Approximating the living","volume":"175","author":"Phillips","year":"2025","journal-title":"Semin Cell Dev Biol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:43:44Z","timestamp":1789505024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1359644626001194"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104714","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insight into human allogeneic CAR-T therapy: an open-access dataset","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104714","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104714"}}